Milind Deshpande
Gründer bei SPERO THERAPEUTICS, INC.
Vermögen: 44 979 $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Milind Deshpande
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
The Ohio University
The Ohio University Other Consumer ServicesConsumer Services Central Hockey League operates a professional minor league hockey teams playing in small to medium-sized markets primarily in central and southwestern US states. The league, which was started in 1992, is managed and operated by WPHL, a subsidiary of Global Entertainment Corporation.
65
| College/University | Other Consumer Services | 65 |
Public Company | Biotechnology | 33 | |
Subsidiary | Pharmaceuticals: Major | 32 | |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA.
28
| Operating Division | Investment Managers | 28 |
Bristol-Myers Squibb Pharmaceutical Research Institute
10
| Subsidiary | 10 | |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Clear Creek Bio, Inc.
Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA.
6
| Private Company | Pharmaceuticals: Major | 6 |
Boston University School of Medicine
6
| College/University | Other Consumer Services | 6 |
Santi Therapeutics, Inc.
Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Nayan Therapeutics, Inc.
Nayan Therapeutics, Inc. BiotechnologyHealth Technology Nayan Therapeutics, Inc. operates as a biotechnology company. It focuses on small molecule development for oscular disorders involving rod degeneration. The company is headquartered in Medfield, MA.
2
| Private Company | Biotechnology | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Milind Deshpande
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | General Counsel Chief Operating Officer Corporate Officer/Principal | |
PROGENICS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology OraPharma, Inc. develops and produces drugs for oral diseases. It offers a suite of products to address a range of patient concerns from the foundation of gums, bone, and teeth to the aesthetics of a whiter smile. The company's products include ARESTIN Microspheres, a locally administered antibiotic indicated as an adjunct to scaling and root planning procedures for the reduction of pocket depth in patients with adult periodontitis; and ONSET Approach, a unique delivery system of locally buffered anesthesia that provides faster onset of anesthesia and a comfortable injection. The company was founded in 1996 and is headquartered in Horsham, PA. | Pharmaceuticals: Major | Chief Executive Officer General Counsel Chief Operating Officer | |
University of Notre Dame | College/University | Masters Business Admin Doctorate Degree | |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
CELATOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Chief Executive Officer Portfolio Manager-Equities Portfolio Manager-Equities Analyst-Equity Analyst-Equity Analyst-Equity Analyst-Equity | |
TETRALOGIC PHARMACEUTICALS CORPORATION | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ASTRIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Annovation BioPharma, Inc.
Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | Pharmaceuticals: Major | Director/Board Member Founder | |
Arteaus Therapeutics LLC
Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | Biotechnology | Founder Founder | |
TRANSLATE BIO, INC. | Biotechnology | Founder Director/Board Member Director/Board Member | |
The Trustees of Columbia University in The City of New York | College/University | Masters Business Admin Graduate Degree Undergraduate Degree Doctorate Degree | |
Duke University
Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree Undergraduate Degree | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Director/Board Member Undergraduate Degree Graduate Degree Undergraduate Degree Doctorate Degree | |
Morrison & Foerster LLP
Morrison & Foerster LLP Miscellaneous Commercial ServicesCommercial Services Morrison & Foerster LLP is a law firm that provides legal services on various industries, which include: litigation, financial services, intellectual property and technology, and transactional work, such as corporate, capital markets and real estate finance representations. The company was founded in 1883 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree Doctorate Degree | |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Consultant / Advisor Consultant / Advisor Private Equity Investor Consultant / Advisor | |
Emory University | College/University | Doctorate Degree Corporate Officer/Principal | |
INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Massachusetts Institute of Technology | College/University | Masters Business Admin Corporate Officer/Principal Doctorate Degree Undergraduate Degree Undergraduate Degree | |
Hillsdale College | College/University | Undergraduate Degree Undergraduate Degree | |
The Johns Hopkins University | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree | |
Yale University | College/University | Graduate Degree Undergraduate Degree Masters Business Admin Undergraduate Degree Undergraduate Degree | |
University of Illinois | College/University | Undergraduate Degree Doctorate Degree | |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Biotechnology | Chief Executive Officer Human Resources Officer | |
AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
EDITAS MEDICINE, INC. | Biotechnology | Director of Finance/CFO Director/Board Member | |
CIDARA THERAPEUTICS, INC. | Pharmaceuticals: Other | Director of Finance/CFO Director/Board Member | |
INTELLIA THERAPEUTICS, INC. | Biotechnology | Founder Chairman | |
VOR BIOPHARMA INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
Jnana Therapeutics, Inc.
Jnana Therapeutics, Inc. BiotechnologyHealth Technology Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA. | Biotechnology | Founder Director/Board Member | |
LARIMAR THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman | |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Medical/Nursing Services | Director/Board Member Director/Board Member Chief Executive Officer | |
Aliada Therapeutics, Inc.
Aliada Therapeutics, Inc. BiotechnologyHealth Technology Aliada Therapeutics, Inc. is a neuroscience-focused company that aims to overcome the delivery hurdle in large molecule drug development. The company is based in Boston, MA. The company is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness. Aliada Therapeutics was founded by Sanjaya Singh, and the CEO is Adam Rosenberg. | Biotechnology | Chief Executive Officer Director/Board Member Director/Board Member | |
RESEARCH ALLIANCE CORP. II | Financial Conglomerates | Chief Executive Officer Founder Director of Finance/CFO | |
Mariana Oncology, Inc.
Mariana Oncology, Inc. BiotechnologyHealth Technology Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets. | Biotechnology | Founder Director/Board Member |
Statistik
International
Vereinigte Staaten | 49 |
Sektoral
Health Technology | 31 |
Consumer Services | 12 |
Finance | 5 |
Commercial Services | 3 |
Health Services | 2 |
Operativ
Director/Board Member | 440 |
Corporate Officer/Principal | 221 |
Independent Dir/Board Member | 112 |
Director of Finance/CFO | 85 |
Undergraduate Degree | 83 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Daniel Geffken | 53 |
Jean-Francois Formela | 47 |
Joshua Resnick | 36 |
Nicholas Simon | 33 |
Peter Kolchinsky | 32 |
Patrick Volkert Vink | 30 |
Nicole Vitullo | 28 |
David Scadden | 26 |
Gary E. Frashier | 26 |
Risa Stack | 25 |
Stephen DiPalma | 24 |
Ankit Mahadevia | 23 |
Burt Adelman | 23 |
Robert van Nostrand | 22 |
Andrew Levin | 21 |
- Börse
- Insiders
- Milind Deshpande
- Unternehmensverbindungen